07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Acuvax, Biolife Science Ltd. deal

Biolife will reverse-merge with Acuvax in a stock deal. Acuvax will issue 20 million of its shares to Biolife up front. Acuvax will own 100% of Biolife and Acuvax will be renamed Biolife Science Ltd....
07:00 , Oct 12, 2009 |  BC Week In Review  |  Clinical News

BvdU: Phase II discontinued

SciClone discontinued a double-blind, placebo-controlled Phase II trial based on the recommendation of an independent DSMC. The company said it is "disappointed with the discontinuation of this study" and it will provide further details when...
07:00 , Apr 20, 2009 |  BC Week In Review  |  Company News

Acuvax, RESprotect deal

Holding company Acuvax sold its 10% stake in cancer company RESprotect to an undisclosed European firm for an undisclosed sum. Acuvax said the deal would improve its cash position by over $750,000. RESprotect's pipeline includes...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

BVdU: Completed Phase II enrollment

SciClone completed enrollment of 153 patients in a double-blind, placebo-controlled, international Phase II trial comparing six cycles of RP101 plus gemcitabine vs. gemcitabine alone. RP101 has Orphan Drug designation to treat pancreatic cancer in the...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Company News

Avantogen board of directors update

Avantogen Ltd. (ASX:ACU), Brisbane, Australia   Business: Cancer, Infectious, Nutraceuticals   Appointed: Pat Elliot, formerly managing director at Natcorp Investments Ltd., as chairman; he replaces William Ardrey, who will remain CEO   ...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

BVdU regulatory update

FDA granted Orphan Drug designation for RP101 for use as an adjunct to treat pancreatic cancer. The nucleoside analog that enhances chemosensitivity and inhibits induced chemoresistance is in Phase II testing to treat advanced pancreatic...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

BVdU: Phase II started

SciClone began a double-blind, placebo-controlled, international Phase II trial in 153 patients to evaluate 6 cycles of gemcitabine with or without RP101 for 3 weeks followed by 1 week of rest. The company licensed U.S....
08:00 , Jan 7, 2008 |  BioCentury  |  Finance

Approval watch

Approval watch Company Product Indication Event Milestone Adolor (NASDAQ:ADLR)/ Entereg alvimopan (ADL 8-2698) Post-operative ileus (POI) FDA panel mtg; 1/23/08 (mtg); GlaxoSmithKline (LSE:GSK; NYSE:GSK) PDUFA date 2/10/08 (PDUFA) Advanced Medical (LSE:AMS) Liquiband Adhesive...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Clinical News

RP101: Phase II start

This quarter, SCLN will start a double-blind, international Phase II trial in 153 patients to evaluate up to six 28-day treatment cycles of RP101 plus gemcitabine or gemcitabine alone. The milestone will trigger a $1.3...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Company News

Avantogen Oncology, RESprotect, SciClone deal

AVTO’s Resistys Inc. subsidiary granted SCLN exclusive rights to develop and commercialize RP101 in the U.S. and Canada to treat cancer. RP101, which inhibits induced chemoresistance and enhances chemosensitivity, has completed Phase I testing...